To make life easier for people with a common bladder condition, Medtronic is digging in far away from urinary tract.

For the first time, a device for releasing local chemotherapy in the bladder has been approved in the U.S., for patients who do not respond to standard treatment.

Findings from studies over 30 years support the integration of chemotherapy and immunotherapy into standard MIBC treatment. For muscle-invasive bladder cancer (MIBC), adjuvant nivolumab following ...

Medtronic has received Food and Drug Administration approval for a neuromodulation therapy in urge urinary incontinence, the company said Friday. The Altaviva device is inserted near the ankle and ...

After implantation, patients are able to return home with the therapy activated; no daily interventions or manual adjustments are required. The Food and Drug Administration (FDA) has cleared Medtronic ...

The Implantable Tibial Neuromodulation (ITNM) device will expand treatment options for the 16 million people living with urinary urges and involuntary leaks GALWAY, Ireland, Sept. 19, 2025 /PRNewswire ...

Urothelial carcinoma (UC) is the second most common genitourinary cancer, leading to over 16,000 deaths a year in the United States. Despite recent advances, the 5-year survival rate for metastatic UC ...

Bladder cancer patients who have an early but aggressive form of the disease that’s unresponsive to the standard of care now have a new treatment option, an implanted Johnson & Johnson drug/device ...

The FDA approved a gemcitabine intravesical system (Inlexzo) for adults with non-muscle-invasive bladder cancer (NMIBC), the agency announced on Tuesday. The indication for the chemotherapy-containing ...

The US Food and Drug Administration has approved Johnson & Johnson’s drug delivery system for a type of bladder cancer, offering a potential surgery-free option for patients. The drug release system, ...

Inlexzo is a new treatment for a type of bladder cancer in adults that hasn’t spread to the muscles and doesn’t respond to Bacillus Calmette-Guérin (BCG) therapy. It’s approved for treating non-muscle ...

(Reuters) - The U.S. Food and Drug Administration has approved Johnson & Johnson's drug delivery system for a type of bladder cancer, offering a potential surgery-free option for patients. The drug ...